InxMed Co., Ltd. ya sanar da cewa an ba da IN0018 tare da Zayyana Nazari na Farko ta Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin. Wannan nadi yana dogara ne akan sakamakon gwajin asibiti na Phase Ib/II na IN10018 don maganin ciwon daji na ovarian mai jure wa platinum, tare da nunin da aka ba da shawarar don maganin ciwon daji na ovarian mai jurewa platinum tare da PEG-liposomal doxorubicin. InxMed yana shirin bayyana ƙarin bayanai akan IN10018 a Taron Shekara-shekara na Societyungiyar Jama'a ta Clinical Oncology a watan Yuni 2022 kuma ya fara gwaji mai mahimmanci a cikin rabin na biyu na shekara.
Hadin gwiwa Tsarin Dalidi yana nufin taimakawa kamfanoni aiki a hankali tare da hukuma don hanzarta bincike, ci gaba, da kuma amincewa da magungunan da ba su dace ba. IN10018 ta karɓi nadi mai sauri daga Hukumar Abinci da Magunguna ta Amurka don kula da marasa lafiya da ke fama da cutar sankarar kwai mai jure wa platinum a watan Agusta 2021. InxMed zai rayu har zuwa babban tsammanin kuma yayi ƙoƙarin isar da fa'idodin sabbin magunguna ga marasa lafiya da wuri-wuri. .
FAK shine mai karɓar tyrosine kinase da mai watsawa wanda ke taka muhimmiyar rawa a cikin mannewar tantanin halitta, ƙaura, da tsari. Yana nuna haɓakar magana a cikin nau'ikan ƙari da yawa. Masu bincike sun gano cewa hana hanyar siginar FAK na iya juyar da maganin chemotherapy a baya da aka yi niyya ta hanyar juriya na miyagun ƙwayoyi da haɓaka amsawa da ingancin immunotherapy don ingantaccen ciwace-ciwace.
IN10018 mai ƙarfi ne kuma mai zaɓin adenosine triphosphate gasa mai hanawa FAK, kuma InxMed yana da keɓantaccen ci gaban duniya da haƙƙin kasuwanci. Cibiyar Nazarin Fassarar InxMed Nanjing ta gudanar da bincike mai zurfi na asali akan IN10018 da FAK kuma ta buga sakamakon bincike a cikin shahararrun mujallu na ilimi. Bayanan asibiti na farko akan IN10018 ya nuna amincinsa da ingancinsa a cikin nau'ikan ƙari da yawa, kuma sabbin sakamakon bincike da bayanan da suka dace sun nuna cewa IN10018 kuma na iya yin tasiri a cikin hanyoyin haɗin gwiwa. Ana sa ran shawo kan shingen fibrosis mai alaƙa da ƙari da inganta rigakafi na gida, sabili da haka yana da yuwuwar yin aiki a matsayin muhimmin kwayar anka a cikin daidaitawa tare da hanyoyin warkewa daban-daban ciki har da immunotherapy, chemotherapy, da farfasa da aka yi niyya.
InxMed ya kafa shirin ci gaban asibiti na duniya don IN10018. Gwajin gwaji a halin yanzu a Amurka da China an tsara su don maganin ciwon daji na ovarian mai jurewa platinum, NRAS mutant metastatic melanoma, ciwon nono mara sau uku, kansa da wuyansa, ciwon daji na pancreatic, da sauran ciwace-ciwacen ciwace-ciwacen da har yanzu ba su da ingantaccen magani.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- InxMed plans to disclose more data on IN10018 at the Annual Meeting of the American Society of Clinical Oncology in June 2022 and initiate a pivotal trial in the second half of the year.
- This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin.
- Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies.
